lymphoplasmacytic lymphoma (LPL)

January 7, 2020February 14, 2020

FDA Grants Orphan Drug Status to CLR 131 for Lymphoplasmacytic Lymphoma Treatment

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Cellectar BioSciences‘ experimental therapy CLR 131 for lymphoplasmacytic lymphoma (LPL), or Waldenström’s macroglobulinemia, a rare type of ... Read more

February 13, 2019February 14, 2020

X4 Pharmaceuticals Launches Phase 1b Trial Testing Mavorixafor-Imbruvica Combo for Waldenström’s Macroglobulinemia

News

X4 Pharmaceuticals has launched a Phase 1b trial to assess the safety and tolerability of mavorixafor (X4P-001), in combination with Imbruvica (ibrutinib), for the treatment of people with Waldenström’s macroglobulinemia ... Read more

November 3, 2016

Cellectar Reveals Phase 2 Study Design for Investigational Therapy in Lymphoma, Myeloma Patients

News

Cellectar Biosciences has revealed the study design of an upcoming Phase 2 trial examining the investigational compound CLR 131 in multiple myeloma and a number of lymphoma subtypes. The study, which ... Read more